Differential pattern and prognostic significance of CD4 +, FOXP3 + and IL-17 + tumor infiltrating lymphocytes in ductal and lobular breast cancers

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Droeser, Raoul ^a,b   Zlobec, Inti ^c,d   Kilic, Ergin ^e   Güth, Uwe ^a   Heberer, Michael ^b   Spagnoli, Giulio ^b   Oertli, Daniel ^a   Tapia, Coya ^c,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN 17; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DUCTAL BREAST CANCER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBULAR BREAST CANCER; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; CD4 LYMPHOCYTE COUNT; FEMALE; LUNG CARCINOMA; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CD4 LYMPHOCYTE COUNT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; MICROARRAY ANALYSIS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859193457     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-134     Document Type: Article

References (55)

1. Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL. Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 1989, 63:102-111. 10.1002/1097-0142(19890101)63:1<102::AID-CNCR2820630117>3.0.CO;2-T, 2642728.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
3. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010, 184:1630-1641. 10.4049/jimmunol.0902813, 20026736.
4. Luscher U, Filgueira L, Juretic A, Zuber M, Luscher NJ, Heberer M, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 1994, 57:612-619. 10.1002/ijc.2910570428, 8181865.
5. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004, 64:2865-2873. 10.1158/0008-5472.CAN-03-3066, 15087405.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308. 10.1038/nrc2355, 2553205, 18354418.
7. Oble DA, Loewe R, Yu P, Mihm MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3. 2935762, 19338264.
8. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008, 20:241-246. 10.1016/j.coi.2008.04.008, 3319305, 18508251.
9. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
10. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373. 10.1182/blood-2007-11-120998, 2442746, 18354038.
11. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999, 59:3698-3704.
12. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011, 407:348-354. 10.1016/j.bbrc.2011.03.021, 21396350.
13. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, et al. Th17 cells in cancer: help or hindrance?. Carcinogenesis 2011, 32:643-649. 10.1093/carcin/bgr019, 3086699, 21304053.
14. Ferguson DJ. Intraepithelial lymphocytes and macrophages in the normal breast17. Virchows Arch A Pathol Anat Histopathol 1985, 407:369-378. 10.1007/BF00709984, 3931340.
15. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 2005, 446:10-14. 10.1007/s00428-004-1143-9, 15660281.
16. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001, 7:3025-3030.
17. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1992, 12:1463-1466.
18. Murta EF, de Andrade JM, Falcao RP, Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 2000, 86:403-407.
19. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008, 8:57. 10.1186/1471-2407-8-57, 2279136, 18294387.
20. Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun 2010, 10:3. 2964018, 20092246.
21. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 2009, 29:2445-2451.
22. Macchetti AH, Marana HR, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics (Sao Paulo) 2006, 61:203-208.
23. Rakha EA, Aleskandarany M, El Sayed ME, Blamey RW, Elston CW, Ellis IO, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009, 45:1780-1787. 10.1016/j.ejca.2009.02.014, 19286369.
24. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011, 58:1107-1116.
25. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28:105-113. 10.1200/JCO.2009.23.7370, 19917869.
26. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27:1746-1752. 10.1200/JCO.2008.17.9036, 19255331.
27. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006, 24:5373-5380. 10.1200/JCO.2006.05.9584, 17135638.
28. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008, 14:2413-2420. 10.1158/1078-0432.CCR-07-4491, 18413832.
29. Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L, et al. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol 2011, 42:983-990. 10.1016/j.humpath.2010.10.012, 3103605, 21315418.
30. Guth U, Huang DJ, Schotzau A, Dirnhofer S, Wight E, Singer G. Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification. Breast 2010, 19:59-64. 10.1016/j.breast.2009.11.008, 20015652.
31. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003, 2:962-972. 10.1038/nrd1254, 14654795.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
33. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666. 10.1056/NEJMoa051424, 16371631.
34. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997, 3:817-819.
35. de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010, 16:1272-1280. 10.1158/1078-0432.CCR-09-1844, 20145162.
36. Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 2009, 18:(Suppl 3):S137-S140.
37. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005, 17:499-508. 10.1016/j.ceb.2005.08.014, 16107313.
38. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008, 21:1527-1532. 10.1038/modpathol.2008.160, 18820666.
39. Minervini A, Di Cristofano C, Gacci M, Serni S, Menicagli M, Lanciotti M, et al. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. J Urol 2008, 180:1284-1289. 10.1016/j.juro.2008.06.036, 18707725.
40. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010, 29:285-293. 10.1007/s10555-010-9224-5, 20393783.
41. Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol 2009, 31:80-86.
42. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005, 5:42. 10.1186/1471-2407-5-42, 1097720, 15847702.
43. Ben Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls CD4+ CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008, 38:2412-2418. 10.1002/eji.200838318, 18792019.
44. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009, 27:186-192. 10.1200/JCO.2008.18.7229, 19064967.
45. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010, 126:2635-2643.
46. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol 2008, 38:925-927. 10.1002/eji.200838168, 18395862.
47. Siegmund K, Ruckert B, Ouaked N, Burgler S, Speiser A, Akdis CA, et al. Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. J Immunol 2009, 182:2124-2130. 10.4049/jimmunol.0802271, 19201865.
48. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007, 67:8344-8350. 10.1158/0008-5472.CAN-06-3304, 17804750.
49. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286. 10.1016/j.cell.2007.04.034, 1974845, 17570480.
50. Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P, et al. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009, 183:7631-7634. 10.4049/jimmunol.0804308, 19923467.
51. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011, 125:65-72. 10.1007/s10549-010-0831-1, 20229175.
52. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, et al. An evaluation of the clinical significance of FOXP3(+) infiltrating cells in human breast cancer. Breast cancer Res Treat 2011, 127:99-108. 10.1007/s10549-010-0987-8, 20556505.
53. Gobert M, Treilleux I, driss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009, 69:2000-2009. 10.1158/0008-5472.CAN-08-2360, 19244125.
54. Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res 2009, 69:7895-7898. 10.1158/0008-5472.CAN-09-1642, 19808962.
55. Wolf D, Wolf AM, Tzankov A. Comment on "Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice". J Immunol 2010, 184:4051.